EPM News Update
Aptuit has appointed two new members to its Executive Leadership team. Kurt Dinkelacker has been named Executive Vice President and Chief Financial Officer and Kevin Duffield has been promoted to Vice President, Sales and Business Development.
As Executive Vice President and Chief Financial Officer, Dinkelacker is reporting directly to Stuart Needleman, Aptuit’s President and COO. Dinkelacker brings substantial experience in managing global financial operations in growth-focused corporations. Previously, he was Executive Vice President and CFO at Retrievex, also a Welsh, Carson, Anderson & Stowe portfolio company. Before that, he held leadership positions at Financing Alternatives, TeleSpectrum Worldwide and IKON Office Solutions. A graduate of Drexel University where he earned a BA in Accounting and an MBA in its Executive graduate programme, Dinkelacker is the recipient of the University’s 1998 Alumni Award.
Duffield takes on new responsibilities as Aptuit’s Vice President, Sales and Business Development. He will be handling global sales and marketing, also reporting directly to Needleman. While the coordinated sales effort continues to be focused at the site function level, under Duffield’s leadership, all sales efforts will be leveraged. Under his supervision, cross selling initiatives and new opportunities from Aptuit’s vast range of capabilities and disciplines are anticipated. Duffield has more than 25 years experience in pharmaceutical contract manufacturing services. He has held several leadership positions in sales, business development, and operations of cGMP development and manufacturing facilities. Before he joined Aptuit, Duffield gained diverse experience while he was employed at Eastman Fine Chemicals, ChiRex and NovaSep. Duffield holds a Bachelor’s Degree in Chemistry from Illinois State University.
In discussing these new appointments, Needleman said: “We congratulate these professionals and look forward to their contributions to our Executive Leadership team. We’ve put a great deal of effort in finding the people who represent our ‘uncommon expertise’ across a range of disciplines. These two proven pros are valuable additions to our team, ready to implement a strategy that will help steer Aptuit to its position as a market-leading provider of early to mid-phase integrated drug discovery and development.”
Aptuit LLC, +1 203 422 6600, info@aptuit.com, www.aptuit.com.